State of the Biopharmaceutical Industry 2023

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Accessing in-depth insights from the ‘State of the Biopharmaceutical Industry’ report will help you –

  • Examine the current attitudes of business leaders towards the emerging trends impacting the biopharmaceutical industry in the next 12 months.
  • Understand the most impactful emerging technologies – Industry, Regulatory and Macroeconomic factors that are going to impact and dominate the industry throughout 2023.
  • Identify the most impactful anticipated regulatory approvals and drug launches in the industry in 2023, highlight top-selling drugs (2022 vs 2023), and overview the clinical trials landscape for 2023.
  • Uncover the healthcare industry professionals’ sentiment about the industry’s growth prospects during the next 12 months and how this sentiment changed over the past 3 years.

How is the ‘State of the Biopharmaceutical Industry’ report different from other reports in the market?

  • It measures which themes are going to have the greatest positive or negative impact on the pharmaceutical industry in 2023.
  • It provides a qualitative analysis of the top regions (Europe, North America, and APAC).
  • It analyzes key emerging trends (regulatory and macroeconomic trends) as well as emerging technologies.
  • The State of the Biopharmaceutical Industry report highlights the planned clinical trials, projected clinical trails completions, top-selling drugs, and drug launches that are going to happen in 2023.
  • Understand other topics that GlobalData identified as important for you (Inflation Reduction Act, prospects of deflation, the rise of ESG, and reshoring of pharmaceutical manufacturing) and adjust your business development strategies.

 We recommend this valuable source of information to anyone involved in:

  • Pharmaceutical Companies
  • Biotech
  • CMOs, CMOs, and CDMOs
  • Consulting Companies
  • Technology Companies and Start-ups
  • Professional Services (e.g., Investment, Equity Companies, Banks)

To Get a Snapshot of the State of the Biopharmaceutical Industry Report, Download a Free Report Sample

State of the Biopharmaceutical Industry Report Overview

The pharmaceutical industry has long been labeled as recession-proof, as medicines are essential products that cannot be completely replaced. However, the looming global recession is likely to have implications on healthcare budgets, forcing governments and regulators to put more stringent laws in place around drug pricing and market access. At the same time, the pharmaceutical industry will have to deal with increased drug development costs that will affect their margins.

The state of the biopharmaceutical industry research report examines the business environment and trends that are going to shape the biopharmaceutical industry in 2023. The report highlights the most impactful emerging technologies, industry, regulatory, and macroeconomic factors that are going to impact and dominate the industry throughout 2023.

Key Findings of the Biopharmaceutical Industry

In 2023, businesses will face turbulent times, and the pharmaceutical industry is not an exception. Financial and costs pressures, as well as increasing regulations and an uncertain economic outlook will be contributing to decreased levels of optimism in growth prospects. To sustain growth, the pharmaceutical industry will need to innovate.

Furthermore, to remain competitive, businesses need to ensure integration, cost-effectiveness, efficiency, and customer excellence, as well as to attain innovative solutions and investor support. Vertical integration, patent expiry of biologics, mega M&As, and ESG factors are anticipated to have the greatest positive impact on the pharmaceutical industry. In addition, big data and AI will continue to dominate as transformational forces in the healthcare sector in 2023.

Emerging Industry Trends in the Biopharmaceutical Industry

The key emerging industry trends in the biopharmaceutical industry are genomics, immuno-oncology drug development, personalized/precision medicine, real-world evidence, remote patient monitoring, electronic health records, biosimilar uptake, decentralized/virtual clinical trials, digital therapeutics, and patient empowerment among others. Genomics is identified as the top emerging pharmaceutical industry trend for 2023.

Biopharmaceutical Industry Analysis, by Emerging Trends, 2023 (%)

Biopharmaceutical Industry Analysis, by Emerging TrendsFor more emerging trend insights in the biopharmaceutical industry, download a free report sample

Emerging Technologies in the Biopharmaceutical Industry

The key emerging technologies impacting the biopharmaceutical industry are AI, big data, cybersecurity, digital media, social media, virtual and augmented reality, IoT, robotics, application programming interfaces, cloud computing, 3-D printing, and blockchain among others. Across all geographies, AI, followed by big data are expected to have the biggest impact on the pharmaceutical industry in 2023.

Biopharmaceutical Industry, by Emerging Technologies, 2023 (%)

Biopharmaceutical Industry, by Emerging TechnologiesFor more emerging technology insights in the biopharmaceutical industry, download a free report sample

Biopharmaceutical Industry Value Chain

The value chain of the biopharmaceutical industry includes supply chain, drug development, end-user experience, physician-targeted sales and marketing, drug discovery, manufacturing, and patient-targeted sales and marketing. Supply chain and manufacturing will be impacted the most by inflation in 2023.

Therapy Areas in the Biopharmaceutical Industry

The top therapy areas for planned clinical trials to be initiated in 2023 in the biopharmaceutical industry are oncology, central nervous system, infectious disease, cardiovascular, gastrointestinal, metabolic disorders, respiratory, immunology, musculoskeletal disorders, and dermatology. Oncology trials will outnumber CNS and infectious disease trials.

Biopharmaceutical Industry, by Therapy Areas (To be Initiated in 2023, %)

Biopharmaceutical Industry, by Therapy Areas (To be Initiated in 2023)For more insights on the therapy areas in the biopharmaceutical industry, download a free report sample

Biopharmaceutical Industry – Competitive Landscape

Top industry sponsors for trials projected to be completed in 2023 are AstraZeneca, Novartis, Johnson & Johnson (J&J), F Hoffman La Roche, Pfizer, Eli Lily, Merck, Abbvie, and GSK among others. AstraZeneca, Novartis, and Johnson & Johnson (J&J) will likely complete the most industry trials in 2023.

Biopharmaceutical Industry, by Industry Sponsors, 2023 (%)

Biopharmaceutical Industry, by Industry SponsorsFor more industry sponsor insights in the biopharmaceutical industry, download a free report sample

Biopharmaceutical Industry Report Overview

Key Emerging Trends Genomics, Immuno-Oncology Drug Development, Personalized/Precision Medicine, Real-World Evidence, Remote Patient Monitoring, Electronic Health Records, Biosimilar Uptake, Decentralized/Virtual Clinical Trials, Digital Therapeutics, and Patient Empowerment
Key Emerging Technologies AI, Big Data, Cybersecurity, Digital Media, Social Media, Virtual and Augmented Reality, IoT, Robotics, Application Programming Interfaces, Cloud Computing, 3-D Printing, and Blockchain
Key Value Chain Supply Chain, Drug Development, End-User Experience, Physician-Targeted Sales and Marketing, Drug Discovery, Manufacturing, and Patient-Targeted Sales and Marketing
Key Therapy Areas Oncology, Central Nervous System, Infectious Disease, Cardiovascular, Gastrointestinal, Metabolic Disorders, Respiratory, Immunology, Musculoskeletal Disorders, and Dermatology
Key Industry Sponsors AstraZeneca, Novartis, Johnson & Johnson (J&J), F Hoffman La Roche, Pfizer, Eli Lily, Merck, Abbvie, and GSK

Biopharmaceutical Industry Therapy Areas Outlook (2023)

  • Oncology
  • Central Nervous System
  • Infectious Disease
  • Cardiovascular
  • Gastrointestinal
  • Metabolic Disorders
  • Respiratory
  • Immunology
  • Musculoskeletal Disorders
  • Dermatology


This report provides:

  • A snapshot of current attitudes of business leaders toward the emerging industry trends and how they are shaping the future of the healthcare industry
  • Overview of the hindrances and drivers that will affect the state of the biopharmaceutical industry
  • Emerging technologies that are expected to have the greatest impact on the biopharmaceutical industry in the next 12 months
  • Executives’ opinions on the growth prospects of the biopharmaceutical industry over the next 12 months
  • Key industry shake-ups and trends to watch that represent both challenges and opportunities to the industry

Reasons to Buy

  • Stay up to date with the major emerging technologies and regulatory, macroeconomic, and industry trends that will impact the pharmaceutical industry in 2023.
  • Explore how the biopharmaceutical landscape has changed
  • Identify the most impactful anticipated regulatory approvals and drug launches in the industry in 2023
  • Gain insight into the regulatory and microeconomics trends that will have positive and negative effects on the biopharmaceutical industry
  • Identify emerging industry trends and innovations to gain a competitive advantage

Acceleron Pharma
Atara Biotherapeutics
Beta Pharma
BioMarin Pharmaceutical
Bio-Thera Solutions
Boehringer Ingelheim
Bristol-Myers Squibb
Celerity Pharmaceuticals
Coherus BioSciences
CSL Behring
CStone Pharmaceuticals
CVS Health Corp
Eli Lilly
Ferring Pharmaceuticals
Fuji Pharma
Insud Pharma
Johnson & Johnson
Johnson Matthey
Legend Biotech
Loxo Oncology
Medicaid Health Plans of America
Merck & Co
Metrics Contract Services
Midas Pharma
Mirati Therapeutics
National Institute for Health and Care Excellence
Nippon Kayaku
Ono Pharmaceutical
OS Therapies
PTC Therapeutics
Regeneron Pharmaceuticals
Samsung Bioepis
Sarepta Therapeutics
Shanghai Junshi Bioscience
Sino Biopharmaceutical
Stada Arzneimittel
Stelis Biopharma
Sumitomo Dainippon Pharma Oncology
Teva Pharmaceutical Industries
TRACON Pharmaceuticals
UnitedHealth Group
Xbrane Biopharma

Table of Contents

1. Executive Summary

2. Study Design

3. Emerging Industry Trends

4. Emerging Regulatory and Macroeconomic Trends

5. Emerging Technologies

6. Industry Growth Prospects

7. Watch Outs

8. Summary of Key Findings

9. Appendix 1

10. Appendix 2

11. Contact Us

Frequently asked questions

State of the Biopharmaceutical Industry 2023 thematic reports
Currency USD

Can be used by individual purchaser only


Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

State of the Biopharmaceutical Industry 2023 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at State of the Biopharmaceutical Industry 2023 in real time.

  • Access a live State of the Biopharmaceutical Industry 2023 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.